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Abstract This study presents the first evaluation of new
Toxoplasma gondii recombinant chimeric antigens containing
three immunodominant regions of SAG2, GRA1, and one of
two ROP1 fragments differing in length for the serodiagnosis
of human toxoplasmosis. The recombinant chimeric antigens
SAG2-GRA1-ROP1L (with large fragment of ROP1, 85–396
amino acid residues) and SAG2-GRA1-ROP1S (with a small
fragment of ROP1, 85–250 amino acid residues) were obtain-
ed as fusion proteins containing His6-tags at both ends using
an Escherichia coli expression system. The diagnostic utility
of these chimeric antigens was determined using the enzyme-
linked immunosorbent assay (ELISA) for the detection of
specific anti-T. gondii immunoglobulin G (IgG). The IgG
ELISA results obtained for the chimeric antigens were com-
pared to those obtained for the use of Toxoplasma lysate anti-
gen (TLA) and for a mixture of recombinant antigens contain-
ing rSAG2, rGRA1, and rROP1. The sensitivity of the IgG
ELISAwas similar for the SAG2-GRA1-ROP1L chimeric an-
tigen (100 %), the mixture of three proteins (99.4 %) and the
TLA (97.1 %), whereas the sensitivity of IgG ELISAwith the
SAG2-GRA1-ROP1S chimeric antigen was definitely lower,
reaching 88.4 %. In conclusion, this study shows that SAG2-
GRA1-ROP1L chimeric antigen can be useful for
serodiagnosis of human toxoplasmosis with the use of the
IgG ELISA assay. Therefore, the importance of proper selec-
tion of protein fragments for the construction of chimeric
antigen with the highest reactivity in ELISA test is
demonstrated.
Keywords ELISA . Serological detection . Chimeric
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Introduction
Toxoplasmosis is a widespread disease caused by the obligate
intracellular parasite Toxoplasma gondii, which can infect a
wide range of hosts, including humans (Tenter et al. 2000).
The World Health Organization (WHO) calculated that one
third of the human population is infected with T. gondii. In
healthy individuals, the primary infection is generally asymp-
tomatic or causes relatively mild flu-like symptoms. However,
the disease is a major threat to immunocompromised individ-
uals and pregnant women. For immunocompromised patients,
infection with T. gondii may cause serious problems, such as
fever, headache, encephalitis, pneumonia, myocarditis, con-
junctivitis, and nervous system damage (Ambroise-Thomas
2001). In pregnant women, toxoplasmosis may pose serious
problems because of transplacental transmission which can
cause fetal abortion. The primary infection can also lead to
premature birth of fetus, neonatal malformation, neurological
damage, and blindness (Dunn et al. 1999; Fatoohi et al. 2002).
Currently, the assays for the diagnosis of toxoplasmosis
primarily use an extract of whole T. gondii tachyzoites grown
in mice or tissue cultures. Although the TLA is characterized
by high sensitivity and specificity in the immunoassay tests,
long and expensive procedures that require a parasite culture
are the biggest disadvantage of the production of the T. gondii
lysate. An additional drawback may be a problem with the
standardization of the tests, which is a direct result of the
quality of the obtained TLA. This is correlated with
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differences in culturing procedures and methods of lysate
preparation between individual laboratories. Moreover, in
some cases, the results obtained for commercial tests are am-
biguous, which does not allow correct diagnosis.
Unfortunately, the appropriate diagnosis can be crucial, espe-
cially for pregnant women or any immunocompromised per-
son. For these reasons, intensive research of recombinant an-
tigens and their mixtures to replace the TLA in ELISA tests is
being carried out. The usefulness of the recombinant antigens
and/or mixture of several recombinant proteins in the detec-
tion of specific IgG and IgM anti-T. gondii antibodies is
broadly evidenced (Holec-Gąsior 2013). In recent years, a
completely new approach has been proposed with the use of
recombinant chimeric antigens containing different immuno-
reactive regions from several selected T. gondii antigens. Until
now, there were only a few studies demonstrating the useful-
ness of the recombinant chimeric antigens in the detection of
specific anti-T. gondii antibodies in human sera (Beghetto
et al. 2006; Dai et al. 2012, 2013; Holec-Gąsior et al. 2012a,
b; Lau et al. 2011).
The aim of the present study is the evaluation of a new
SAG2-GRA1-ROP1 chimeric antigen for ELISA tests for
serodiagnosis of human toxoplasmosis and demonstration of
the importance of proper selection of protein fragments for the
construction of the chimeric antigen with the highest reactivity
in the ELISA test. Selection of these antigens for the construc-
tion of chimeric protein was based on earlier results obtained
in the immunoassays, which determined the reactivity of these
proteins with specific anti-T. gondii antibodies. The SAG2
antigen, which is identified as an intrinsically unstructured
protein, can interact with many cellular and surface molecules
of infected host (Macedo et al. 2013). In previous studies, the
usefulness of the recombinant SAG2 antigen was shown to be
effective in detecting specifically anti-T. gondii antibodies in
sera especially from the acute, but also from the chronic phase
of toxoplasmosis (Hiszczyńska-Sawicka et al. 2005; Lau and
Fong 2008; Li et al. 2000; Parmley et al. 1992). The GRA1
antigen, which plays an important role in the structural mod-
ifications of parasitophorous vacuole, is also associated with
strong stimulation of the host immune system (Cesbron-
Deleuw et al. 1989; Coppens et al. 1999). In GRA1, the
immunodominant epitope involved in the human B-cell re-
sponse against the parasite was identified and this suggests
that GRA1 antigen can be used as a marker of the chronic
phase of toxoplasmosis (Cesbron-Deleuw et al. 1989;
Beghetto et al. 2001). Serological studies with recombinant
GRA1 antigen demonstrated that this protein can be used to
detect specific IgG in sera of both acute and chronic phase of
disease (Hiszczyńska-Sawicka et al. 2003; Lecordier et al.
2000; Pietkiewicz et al. 2007). The ROP1 protein is involved
at an early stage of the parasite invasion into host cells. The
evidence of this is the fact that ROP1 is secreted into the
interior of the forming parasitophorous vacuole during
parasite entry into host cells, and its expression is inhibited a
few hours after the invasion (Bradley et al. 2002; Soldati et al.
1998). For this reason, the ROP1 protein is considered to be a
marker for the differentiation between acute and chronic toxo-
plasmosis, which has been confirmed in immunoassays
(Holec-Gąsior et al. 2009, 2010).
Materials and methods
Construction of the recombinant plasmid
The pUET1/SAG2 (Hiszczyńska-Sawicka et al. 2005),
pUET1/GRA1 (Hiszczyńska-Sawicka et al. 2003), and
pUET1/ROP1 (Holec-Gąsior et al. 2009) recombinant plas-
mids were used as templates for amplification of correct DNA
fragments using a standard PCR amplification protocol with
the Delta3 DNA polymerase (BLIRT S.A., Gdansk, Poland).
DNA fragments of sag2, gra1, rop1S, and rop1L were ampli-
fied using S1, S2, G1, G2, R1, R2, and R3 primers (Table 1).
PCR products of sag2 and gra1 were then mixed and used as
templates in a PCR with S1 and G2 primers. sag2/gra1 and
rop1S and rop1L products were then mixed and used as tem-
plates in a PCR with the primers pairs S1 + R2 and S1 + R3,
which were designed to contain BglII and EcoRV recognition
sequences to facilitate cloning. The final PCR products were
digested with both BglII and EcoRVand inserted into the BglII
and EcoRV sites of the pET-30 Ek/LIC vector (Novagen,
Madison, WI, USA). The nucleotide sequences of the
resulting recombinant plasmids were confirmed by DNA se-
quencing (Genomed, Poland). The pET-30/SAG2-GRA1-
ROP1S and pET-30/SAG2-GRA1-ROP1L plasmids contained
a sequence of SAG2, amino acid residues 31–170, a sequence
of GRA1, amino acid residues 26–190, and a sequence of
ROP1, amino acid residues 85–250 and 85–396, which were
embedded in a frame between the His6-tag domains for puri-
fication of the recombinant proteins bymeans of metal affinity
chromatography.
Expression and purification of the chimeric antigens
and recombinant proteins
E. coli strain Rosetta(DE3)pLacI, transformed with pET-30/
SAG2-GRA1-ROP1S or pET-30/SAG2-GRA1-ROP1L re-
combinant plasmid, was grown 16 h at 30 °C in LB media
supplemented with 100 μg/ml of ampicillin and 34 μg/ml of
chloramphenicol. Following day, 1000 ml of LB medium,
supplemented with the same antibiotics, was inoculated with
20 ml of the overnight culture. The cultures were grown with
vigorous shaking at 30 °C to the optical density at 600 nm
(OD600) of 0.4. Protein production was then induced with
isopropyl-β-D-thiogalactopyranoside (IPTG) to a final con-
centration of 1 mM, and the cells were incubated with
3292 Parasitol Res (2015) 114:3291–3299
vigorous shaking for an additional 18 h at 30 °C. Cells were
then harvested by centrifugation, and the pellets were resus-
pended in 30 ml of buffer A (20 mM Tris–HCl pH 7.9,
500 mM NaCl, 5 mM imidazole, 0.1 % Triton X-100). The
cells were disrupted by sonication, and the insoluble debris
was removed by centrifugation. The protein was purified from
the supernatant using a Ni2+-iminodiacetic acid-Sepharose
column in accordance with the manufacturer’s instructions
(Novagen, Madison, WI, USA).
Recombinant proteins SAG2 (from 31 to 170 amino acid
residues), GRA1 (from 26 to 190 amino acids), and ROP1
(from 85 to 396 amino acid residues) were produced as pre-
viously described (Hiszczyńska-Sawicka et al. 2003, 2005;
Holec-Gąsior et al. 2009). TLAwas prepared from tachyzoites
(RH strain) as described earlier (Holec-Gąsior et al. 2009).
The recombinant proteins were analyzed by means of SDS-
PAGE on 12 % acrylamide gels and stained with Coomassie
blue. The concentrations of the purified proteins were deter-
mined by the Bradford method using bovine serum albumin as
the standard.
Human serum samples
All of the serum samples used in this study were received
during routine toxoplasmosis screening. The samples were
previously collected with prior informed consents of the indi-
viduals. Approval for use of the banked samples was obtained
from Medical University of Gdańsk Human Research Ethics
Committee. A total of 295 sera were analyzed and divided into
four groups in accordance with the results obtained using the
commercial tests VIDAS TOXO IgM, VIDAS TOXO IgG II,
and VIDAS TOXO IgG AVIDITY (bioMérieux, Marcy
l'Etoile, France). Group I serum samples were collected from
41 patients with suspected acute phase of toxoplasmosis. All
of these sera had specific IgM and IgG antibodies with low
avidity. Group II consisted of 17 serum samples received from
patients with suspected postacute phase of toxoplasmosis.
Selectionwas based on the presence of specific IgG antibodies
with low or borderline avidity and an absence of specific IgM
antibodies. Group III included 114 sera from patients with
chronic toxoplasmosis. All of these serum samples had IgG
antibodies with high avidity and specific IgM antibodies were
not detected. Moreover, the serum samples from this group
were further divided into three subgroups based on IgG titers:
IIIA consisted of 17 serum samples with high value of IgG
antibodies (over 300 IU/ml), IIIB included 34 serum samples
with values of IgG antibodies between 101 to 300 IU/ml, and
IIIC consisted of 63 serum samples with low values of IgG
antibodies below 100 IU/ml. The last group, IV, was a control
group of 123 human serum samples from seronegative
patients.
IgG ELISA
MaxiSorp multiwell plates (Nunc, Roskilde, Denmark) were
coated with chimeric antigens SAG2-GRA1-ROP1S, SAG2-
GRA1-ROP1L, and a mixture of proteins (rSAG2, rGRA1,
and rROP1) or with TLA at final concentrations of
2.5 μg/ml for each recombinant protein and 1 μg/ml for the
TLA in a coating buffer (0.05 M carbonate buffer, pH 9.6).
After overnight incubation at 4 °C, the plates were washed
three times with PBS-0.1 % Triton X-100 and blocked for
1 h at 37 °C in blocking solution (1 % bovine serum albumin,
0.5 % Triton X-100 in PBS). The cells were then washed three
times and incubated for 1 h at 37 °C with the human serum
diluted 1:100 in blocking solution. Next, the plates were
washed three times with washing buffer and incubated with
anti-human IgG peroxidase-labeled conjugates (Jackson
Table 1 Oigonucleotide primers used for construction of the SAG2-GRA1-ROP1S ant the SAG2-GRA1-ROP1L chimeric antigens
T. gondii gene(s) Primer name Primer sequence Underlined sequence Template for
amplification
sag2 S1 (forward) 5′-GACAGCACAGATCTGACGCCAGCGCCCATTG-3′ BglII and fragment of sag2 pUET1/SAG2
S2 (reverse) 5′-GTTGTCGCCGCCTTCCGTGAGAGACACAGG-3′ Fragments of gra1 and sag2
gra1 G1 (forward) 5′-CCTGTGTCTCTCACGGAAGGCGGCGACAAC-3′ Fragments of sag2 and gra1 pUET1/GRA1
G2 (reverse) 5′-CGGGCCTCTGACAGGCTCTCTCTCTCCTG-3′ Fragments of rop1 and gra1
rop1S R1 (forward) 5′-CAGGAGAGAGAGAGCCTGTCAGAGGCCCG-3′ Fragments of gra1 and rop1 pUET1/ROP1
R2 (reverse) 5′-CGGATCCGATATCGCACGACCTGGTCCCTGC-3′ EcoRVand fragment of rop1
rop1L R1 (forward) 5′-CAGGAGAGAGAGAGCCTGTCAGAGGCCCG-3′ Fragments of gra1 and rop1 pUET1/ROP1
R3 (reverse) 5′-CGGCTCCGATATCGCTTGCGATCCATCATCCTG-3′ EcoRVand fragment of rop1
sag2/gra1 S1 (forward) Same as above Same as above pre-sag2/gra1
G2 (reverse) Same as above Same as above
sag2/gra1/rop1S S1 (forward) Same as above Same as above pre-sag2/gra1/rop1S
R2 (reverse) Same as above Same as above
sag2/gra1/rop1L S1 (forward) Same as above Same as above pre-sag2/gra1/rop1L
R3 (reverse) Same as above Same as above
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ImmunoResearch, Newmarket, Suffolk, UK) diluted 1:16,000
in blocking solution for 1 h at 37 °C, after which o-
phenylenediamine dihydrochloride chromogenic substrate
(Sigma-Aldrich, Dorset, UK) was added. After 45 min of
incubation at 37 °C in darkness, the reaction was stopped by
the addition of 0.1 M sulfuric acid and the OD492 was mea-
sured using a microtiter plate reader (Multiskan FC; Thermo
Scientific).
Each serum sample was examined twice. The results were
determined for each sample by calculating the mean OD read-
ing of duplicate wells. A positive result was defined as any
value higher than the average OD reading plus 2 standard
deviations (cutoff) obtained with 23 serum samples from the
control, group IV, which consisted of seronegative serum sam-
ples. The calculated cutoff values were 0.281 for the SAG2-
GRA1-ROP1S, 0.389 for rSAG2-GRA1-ROP1L, 0.504 for
SAG2, GRA1, and ROP1 mixture, and 0.507 for TLA.
Statistical analysis
Means and range of the IgG ELISA absorbancemeasurements
for the sera from different groups, and the sensitivity, speci-
ficity, and positive and negative predictive values of IgG
ELISA assays are given.
Results
Expression and purification of the SAG2-GRA1-ROP1S
and SAG2-GRA1-ROP1L chimeric antigens
The SAG2-GRA1-ROP1S and SAG2-GRA1-ROP1L were
expressed as soluble proteins with a calculated molecular
mass of 56.4 and 72.2 kDa, respectively. The proteins were
purified by a one-step chromatography procedure by metal
affinity chromatography with Ni2+ bound to iminodiacetic
acid-agarose (Novagen). The expression system applied pro-
duces about 33 and 31 mg of purified SAG2-GRA1-ROP1S
and SAG2-GRA1-ROP1L proteins from 1 liter of induced
culture, respectively. The purification resulted in an electro-
phoretically homogeneous preparations with a purity above
95 % (results not shown).
Immunoreactivities of T. gondii IgG antibodies in ELISAs
with chimeric antigens, mixture of recombinant proteins,
and TLA
All of the groups of human serum samples, namely, group I
(sera from patients in the acute phase of toxoplasmosis), group
II (sera from patients in the postacute phase of toxoplasmosis),
group III (sera from patients in the chronic phase of toxoplas-
mosis), and group IV (sera from seronegative individuals),
were examined by means of IgG ELISAs conducted with
the SAG2-GRA1-ROP1S and SAG2-GRA1-ROP1L chimeric
antigens, a mixture of recombinant antigens (rSAG2, rGRA1,
and rROP1), and TLA. Twenty-three sera from group IV
(seronegative) were tested in order to calculate cutoff values
for all of the IgG ELISAs, which were set as the mean value of
the negative serum samples plus 2 standard deviations.
Moreover, the remaining 100 sera from this group were used
to determine the specificity of the IgG ELISAs. None of these
sera reacted above the cutoff value in the IgG ELISA; there-
fore, the specificity was 100 % (Table 2).
The sensitivity of the IgG ELISA with the SAG2-GRA1-
ROP1L chimeric antigen (containing longer fragment of
ROP1 protein corresponding to amino acid residues 85–396)
calculated for all of the positive serum samples was 100 %
(Table 2). This value was the highest obtained among the IgG
ELISAs and was comparable to IgG ELISAs carried out with
the mixture of recombinant antigens (rSAG2, rGRA1, and
rROP1), and TLA, whose sensitivity was slightly lower and
amounted to 99.4 and 98.8 %, respectively. Much lower sen-
sitivity at 88.4 % was obtained for the IgG ELISA with the
SAG2-GRA1-ROP1S chimeric antigen (which contained a
shorter fragment of ROP1 protein corresponding to amino
acid residues 85–250). Examination of the results obtained
for serum samples from patients in the acute phase of toxo-
plasmosis (group I) showed that the IgG antibodies reacted at
100 % with a mixture of recombinant protein (rSAG2,
rGRA1, and rROP1), the SAG2-GRA1-ROP1S and the
SAG2-GRA1-ROP1L chimeric antigens, and the TLA. In
group II consisting of sera from patients in the postacute phase
of toxoplasmosis, specific IgG antibodies reacted from all of
the serum samples in the case of using the SAG2-GRA1-
ROP1L chimeric antigen, the mixture of recombinant proteins
and the TLA (100 %), whereas the reactivity of the IgG anti-
bodies with the SAG2-GRA1-ROP1S chimeric antigen was
lower, at 82.4 %. Moreover, sera from the patients in the
chronic phase of toxoplasmosis, group III, reacted with the
SAG2-GRA1-ROP1L chimeric antigen with the highest reac-
tivity of 100 %, whereas slightly lower reactivity was ob-
served for the mixture of recombinant antigens and the TLA,
at 99.1 and 98.2%, respectively. As in the case of group II, the
lowest reactivity at 85.1 % was noticed for the SAG2-GRA1-
ROP1S chimeric antigen. Additionally, the results obtained for
serum samples of group III were divided into subgroups for
the IgG antibody titers. Thus, all of the serum samples from
subgroup IIIA (IgG antibodies value >300 IU/ml) reacted at
100%with a mixture of antigens, the tested chimeric antigens,
and the TLA (Fig. 1). The same reactivity was observed for a
mixture of recombinant proteins, the SAG2-GRA1-ROP1L
chimeric antigen, and TLA with sera from subgroup IIIB
(IgG antibodies value between 101 and 300 IU/ml), whereas
the reactivity was much lower for the SAG2-GRA1-ROP1S
chimeric antigen, at 85.3 %. In the case of subgroup IIIC (IgG
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antibodies value ≤100 IU/ml), the reactivity at 100 % was
observed for the SAG2-GRA1-ROP1L, whereas slightly low-
er reactivity was observed for a mixture of recombinant anti-
gens and the TLA, at 98.4 and 96.8 %, respectively. The
lowest reactivity at 81.0 % was noticed for the SAG2-
GRA1-ROP1S chimeric antigen.
Discussion
Until now, there were only a few studies demonstrating the
usefulness of the recombinant chimeric antigens in the
detection of specific anti-T. gondii antibodies. In 2006,
Baghetto et al. showed the usefulness of two chimeric anti-
gens in serological diagnosis of toxoplasmosis. One of those
contained three immunodominant regions of MIC2, MIC3,
and SAG1; the second one contained three fragments of
GRA3, GRA7, and M2AP. In 2011, Lau et al. constructed a
chimeric antigen which was composed of the SAG1 and
SAG2 fragments. The usefulness of this chimeric antigen in
Western blot assays using serum samples from patients with
early acute, acute, and chronic toxoplasmosis was shown. Dai
et al. (2012, 2013) developed a recombinant multiepitope fu-
sion peptide (rMEP) composed of three antigenic
Table 2 Comparison of the immunoreactivities of the mixture of
antigens (M: rSAG2+rGRA1+rROP1), the SAG2-GRA1-ROP1S and
the SAG2-GRA1-ROP1L chimeric antigens, and the TLA using sera
from individuals in the acute, postacute, and chronic phase of
toxoplasmosis and sera from healthy patients
Serum samples group
and antigen













M 41 (100) 2.153 (0.821–3.692) 100 100 100 100
SAG2-GRA1-ROP1S 41 (100) 1.387 (0.293–3.303) 100 100 100 100
SAG2-GRA1-ROP1L 41 (100) 2.143 (0.887–3.626) 100 100 100 100
TLA 41 (100) 1.058 (0.512–1.798) 100 100 100 100
IIc
M 17 (100) 0.972 (0.545–1.786) 100 100 100 100
SAG2-GRA1-ROP1S 14 (82.4) 0.529 (0.185–1.431) 82.4 100 100 97.1
SAG2-GRA1-ROP1L 17 (100) 0.963 (0.482–2.184) 100 100 100 100
TLA 17 (100) 0.925 (0.510–1.976) 100 100 100 100
IIId
M 113 (99.1) 1.531 (0.466–3.237) 99.1 100 100 99.0
SAG2-GRA1-ROP1S 97 (85.1) 0.593 (0.153–1.713) 85.1 100 100 85.5
SAG2-GRA1-ROP1L 114 (100) 1.403 (0.464–3.148) 100 100 100 100
TLA 112 (98.2) 1.298 (0.460–2.165) 98.2 100 100 98.0
Totale
M 171 1.624 (0.466–3.692) 99.4 100 100 99.0
SAG2-GRA1-ROP1S 152 0.778 (0.153–3.303) 88.4 100 100 83.3
SAG2-GRA1-ROP1L 172 1.535 (0.464–3.626) 100 100 100 100
TLA 170 1.204 (0.460–2.165) 98.9 100 100 98.0
IVf
M 0 0.443 (0.192–0.504) – – – –
SAG2-GRA1-ROP1S 0 0.166 (0.104–0.279) – – – –
SAG2-GRA1-ROP1L 0 0.295 (0.109–0.387) – – – –
TLA 0 0.416 (0.213–0.507) – – – –
a The cutoff values were 0.504 for M, 0.281 for SAG2-GRA1-ROP1S, 0.389 for SAG2-GRA1-ROP1L, and 0.507 for TLA
bAcute phase of toxoplasmosis, n=41
c Postacute phase of toxoplasmosis, n=17
d Chronic phase of toxoplasmosis, n=114
eAll of positive serum samples, n=172
f Control group negative for anti-T. gondii antibodies, n=100
g Positive predictive value
hNegative predictive value
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determinants cloned from SAG1, SAG2, and SAG3 antigens
which was effective in discriminating between active and
chronic infections and useful for the detection of IgG and
IgM antibodies. In our previous studies, we also showed the
usefulness of two recombinant chimeric antigens MIC1-
MAG1 (Holec-Gąsior et al. 2012a) and MIC1-MAG1-SAG1
(Holec-Gąsior et al. 2012b) in diagnosis of toxoplasmosis. We
demonstrated that the single recombinant proteins MIC1ex2
and MAG1 or mixtures of proteins (MIC1ex2 and MAG1)
have lower reactivity at the level of 75.5, 60, and 69.1 %,
respectively, than the polyvalent native antigen TLA at
91.8 %. Only the chimeric antigen MIC1-MAG1 had a com-
parable reactivity to the TLA, which amounted to 90.9 %.
Furthermore, in the case of serum samples from patients with
the acute and postacute phase of toxoplasmosis the MIC1-
MAG1 chimeric antigen was characterized by 100 % reactiv-
ity, while the TLA showed lower reactivity at 88.5 %. In the
next study (Holec-Gąsior et al. 2012b), we showed that the
MIC1-MAG1-SAG1 chimeric protein containing three
T. gondii antigen fragments had higher reactivity than the
chimeric antigen MIC1-MAG1, which contained only two
protein fragments. The addition to the chimeric protein of
the fragment of SAG1, which is one of the most immunogenic
parasite proteins, resulted in an increase in the reactivity with
specific IgG anti-T. gondii antibodies. The reactivity of the
IgG ELISA with the MIC1-MAG1-SAG1 chimeric antigen
calculated for all of the positive serum samples was 98.1 %,
while the sensitivity of the IgG ELISAwith the MIC1-MAG1
chimeric antigen or mixture of three recombinant proteins
(rMIC1ex2, rMAG1, and rSAG1) was significantly lower
and amounted 81.5 and 90.7 %, respectively. The result of
our studies showed that in the case of antigen construction
for diagnostic utility, a rational selection of protein fragments
is of great importance. The above described studies show the
potential of recombinant chimeric antigens. Major advantages
of the recombinant chimeric antigens over commonly tested
individual recombinant antigens and/or mixture of those in-
clude (i) higher sensitivity of immunoassay tests and (ii) sim-
plicity to define a quality of the chimeric antigen and to stan-
dardize the method.
In the present study, further work on the utility of the re-
combinant chimeric antigens in IgG ELISA tests for human
toxoplasmosis diagnosis is shown. Three fragments of
T. gondii SAG2, GRA1, and ROP1 proteins were used to
construct two chimeric antigens which contain the same frag-
ment of SAG2 and GRA1 antigens, but a different sizes
Fig. 1 Immunoreactivities of SAG2-GRA1-ROP1S chimeric antigen (a),
SAG2-GRA1-ROP1L chimeric antigen (b), the mixture of recombinant
antigens (M: rSAG2+rGRA1+rROP1) (c), and TLA (d) with sera from
patients with suspected acute (I), postacute (II) phase, and chronic (IIIA
with IgG value >300 IU/ml, IIIB with IgG value from 101 to 300 IU/ml,
and IIIC with IgG value ≤100 IU/ml) phase of toxoplasmosis
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fragment of the ROP1 protein. The SAG2-GRA1-ROP1S and
SAG2-GRA1-ROP1L chimeric antigens were evaluated with
the IgG ELISA. The study demonstrates that, in all of the
positive sera, the sensitivity of IgG ELISA for SAG2-
GRA1-ROP1L chimeric antigen (contains 85–396 amino acid
residues of ROP1) was 100 %. The reactivity of the IgG
ELISA for the mixture of proteins (rSAG2, rGRA1, and
rROP1), and TLA was almost as high as for the SAG2-
GRA1-ROP1L, at 99.4 and 98.8 %, respectively.
Significantly lower reactivity at 88.4 % was reported for IgG
ELISAwith the use of the SAG2-GRA1-ROP1S chimeric an-
tigen (contains 85–250 amino acid residues of ROP1).
Moreover, the specific IgG anti-T. gondii antibodies in indi-
vidual sera from patients with acute phase of toxoplasmosis
reacted at the same level with all antigen preparations. In
group II (sera from patients with postacute phase of toxoplas-
mosis), lower reactivity at 82.4%was noticed only for SAG2-
GRA1-ROP1S chimeric protein. The examination of the sera
from group III, collected from patients with the chronic phase
of toxoplasmosis demonstrated that the sensitivity of IgG
ELISA is associated with IgG titers. Accurate analysis of the
serum samples from this group showed that only the reactivity
of the IgG ELISA with the SAG2-GRA1-ROP1L chimeric
antigen is still high, at 100 %, for sera from all subgroups
(IIIA, IIIB, and IIIC). Furthermore, a slightly lower reactivity,
at 98.4 and 96.8 %, was noticed properly of the IgG ELISA
with the mixture of antigens and the TLA, for sera from pa-
tients with a low IgG value of ≤100 IU/ml in IIIC subgroup
(IgG value of nonreactive serum samples at ≤15 IU/ml). The
lowest reactivity was again observed in the case of the IgG
ELISA with the SAG2-GRA1-ROP1S chimeric antigen, in
subgroup IIIB (IgG value between 101 and 300 IU/ml) at
85.3 % and for subgroup IIIC (IgG value of ≤100 IU/ml) at
81.0 %. Moreover, the mean absorbance values calculated for
all three groups of serum samples showed that the SAG2-
GRA1-ROP1L chimeric antigen, and a mixture of three re-
combinant proteins (rSAG2, rGRA1, and rROP1) resulted in
comparably higher reactivity than TLA, and the SAG2-
GRA1-ROP1S chimeric antigen.
The constructed chimeric antigens contain fragments of
three T. gondii proteins, SAG2, and GRA1 characterized by
the ability to detect IgG antibodies in sera from both acute and
chronic toxoplasmosis (Hiszczyńska-Sawicka et al. 2003,
2005; Lau and Fong 2008; Lecordier et al. 2000; Li et al.
2000; Parmley et al. 1992; Pietkiewicz et al. 2007), and
ROP1, which has been suggested to be a molecular marker
to differentiate between acute and chronic infection (Holec-
Gąsior et al. 2009, 2010). The higher reactivity of the SAG2-
GRA1-ROP1L chimeric antigen (contains 85–396 amino acid
residues of ROP1) than the SAG2-GRA1-ROP1S chimeric
antigen (contains 85–250 amino acid residues of ROP1) can
be explained by the fact that the only construct containing a
bigger fragment of the ROP1 protein was recognized by
specific IgG anti-T. gondii antibodies targeted for the ROP1
antigen. Furthermore, the absorbance values observed for in-
dividual serum samples is a confirmation of this fact, the av-
erage values of the absorbance was twice as high for the
SAG2-GRA1-ROP1L chimeric antigen than for the SAG2-
GRA1-ROP1S chimeric antigen. It is possible that the shorter
fragment of the ROP1 antigen is not as well recognized by
specific IgG antibodies, and absorbance values derived from
the antibodies specifically bound to the fragments of SAG2
and GRA1 antigens. This hypothesis is supported by the re-
sults where the mean absorbance values obtained for the mix-
ture of antigens (rSAG2, rGRA1, and rROP1) and the SAG2-
GRA1-ROP1L chimeric antigen were almost the same.
The study of the ROP1 antigen showed that the amino acid
sequence of these proteins contains an interesting charge
asymmetry suggesting a role in the heterotypic binding of
different proteins (Bradley and Boothroyd 1999; Ossorio
et al. 1992; Soldati et al. 1995). The mature ROP1 protein
has a series of tandem octapeptide repeats rich in proline and
glutamic acid (gives the acidic character of N-terminal region
and center of protein), the antigen also contains a region rich
in arginine (alkaline region in the C-terminal), which may
stabilize the structure of the protein. The SAG2-GRA1-
ROP1L chimeric antigen with a fragment of ROP1 corre-
sponding to 85–396 amino acid residues, contains a part of
the alkaline C-terminal region rich in arginine, which is likely
to be crucial for antigen recognition by the specific antibodies.
The high reactivity of the SAG2-GRA1-ROP1L chimeric an-
tigen can be also explained by another hypothesis. The C-
terminal region of ROP1 may contain at least one
immunodominant B-cell epitope recognized by the majority
of individuals, whereas responses to N-terminal region of
ROP1 are much more variable. In 2000, Lecordier et al.
showed that only the N-terminal hydrophilic part of the
GRA6 protein was recognized by a pool of positive human
sera in an immunoblot, while the same serum samples did not
yield positive results with the C-terminal part of GRA6. In
2008, Holec et al. observed different reactivity values of se-
rum samples from patients with acute and chronic infection in
the IgG ELISAwith the MIC1ex2 (N-terminal part of MIC1),
the MIC1ex34 (C-terminal part of MIC1), and the whole
MIC1. The result also showed that only the N-terminal part
of MIC1 (rMIC1ex2) reacts strongly with both groups of sera
from acute (96.1 %) and chronic (75 %) phase of toxoplasmo-
sis. These results demonstrated that for some antigens the
reactivity of specific IgG antibodies was correlated with a
particular part of the antigen, and probably the same situation
occurred for the ROP1 protein. Moreover, the results obtained
in this study confirm the results from our previous studies,
which indicated that a properly constructed chimeric antigen
containing different immunodominant regions is better than a
mixture of antigens and can be used instead of TLA in
serodiagnosis of human toxoplasmosis.
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To summarize, this report presents results which demon-
strate, for the first time, that during the construction of chime-
ric antigens in addition to a rational choice of proteins which
exhibit strong immunogenic properties, particular attention
should be also paid to the size of protein fragments and its
amino acid sequences. Furthermore, these studies show the
diagnostic usefulness of the new SAG2-GRA1-ROP1L and
SAG2-GRA1-ROP1S chimeric antigens. One of these anti-
gens SAG2-GRA1-ROP1L in the IgG ELISA was character-
ized by a significantly higher reactivity/sensitivity than that
obtained with the TLA or with a mixture of three antigens.
Before the SAG2-GRA1-ROP1L chimeric antigen can be
used instead of the TLA in the clinical diagnosis of toxoplas-
mosis more assays are required; however, the presented results
are very promising.
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